Near-infrared fluorescent probes for imaging of amyloid plaques in Alzheimer's disease

Acta Pharmaceutica Sinica B

Volumn 5, Issue 1, 2015, Pages 25-33

  Tong, Hongjuan ^a   Lou, Kaiyan ^a   Wang, Wei ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Alzheimer's disease; Amyloid plagues; Blood brain barrier; Fluorescence probe; Near infrared fluorescence; Optical imaging

Indexed keywords

AMYLOID BETA PROTEIN; AOI 987; BAP 1; BAP 2; BAP 3; BAP 4; BAP 5; BODIPY 7; CRANAD 17; CRANAD 2; CRANAD 3; CRANAD 58; CURCUMIN; DANIR 2C; DMDAD 3; DMMAD 3; FLUORESCENT DYE; MAAD 3; MCAAD 3; NIAD 11; NIAD 16; NIAD 4; THK 265; UNCLASSIFIED DRUG;

ABSORPTION; ALZHEIMER DISEASE; AMYLOID PLAQUE; BINDING AFFINITY; BINDING SITE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; CHEMICAL STRUCTURE; FLUORESCENCE IMAGING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPOPHILICITY; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; PROTEIN AGGREGATION; QUANTUM YIELD; REVIEW; SYNTHESIS;

EID: 84947202865     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2014.12.006     Document Type: Review

References (67)

1. Thies W., Bleiler L., Alzheimer's Association Alzheimer's disease facts and figures. Alzheimers Dement 2013, 9:208-245.
2. Selkoe D.J. The origins of Alzheimer disease-a is for amyloid. J Am Med Assoc 2000, 283:1615-1617.
3. Hamley I.W. The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. Chem Rev 2012, 112:5147-5192.
4. Savelieff M.G., DeToma A.S., Derrick J.S., Lim M.H. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease. Acc Chem Res 2014, 47:2475-2482.
5. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
6. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
7. Kepp K.P. Bioinorganic chemistry of Alzheimer's disease. Chem Rev 2012, 112:5193-5239.
8. Rauk A. The chemistry of Alzheimer's disease. Chem Soc Rev 2009, 38:2698-2715.
9. Kung H.F. The β-amyloid hypothesis in Alzheimer's disease: seeing is believing. ACS Med Chem Lett 2012, 3:265-267.
10. Poduslo J.F., Wengenack T.M., Curran G.L., Wisniewski T., Sigurdsson E.M., Macura S.I., et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002, 11:315-329.
11. Flaherty D.P., Walsh S.M., Kiyota T., Dong Y., Ikezu T., Vennerstrom J.L. Polyfluorinated bis-styrylbenzene β-amyloid plaque binding ligands. J Med Chem 2007, 50:4986-4992.
12. n in APP/PS1 transgenic mice. Anat Rec 2010, 293:2136-2143.
13. Martins A.F., Morfin J.F., Kubíčková A., Kubíček V., Buron F., Suzenet F., et al. PiB-conjugated, metal-based imaging probes: multimodal approaches for the visualization of β-amyloid plaques. ACS Med Chem Lett 2013, 4:436-440.
14. Sun W.G., Li H.H. Application of MRI molecular probes in the diagnosis of Alzheimer's disease. Prog Anat Sci 2013, 19:464-466.
15. Rowe C.C., Villemagne V.L. Brain amyloid imaging. J Nucl Med Technol 2013, 41:11-18.
16. Mathis C.A., Mason N.S., Lopresti B.J., Klunk W.E. Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med 2012, 42:423-432.
17. Koo J.H., Byun Y. Current status of PET-imaging probes of β-amyloid plaques. Arch Pharm Res 2013, 36:1178-1184.
18. Zhu L., Ploessl K., Kung H.F. PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev 2014, 43:6683-6691.
19. Henriksen G., Yousefi B.H., Drzezga A., Wester H.J. Development and evaluation of compounds for imaging of β-amyloid plaque by means of positron emission tomography. Eur J Nucl Med Mol Imag 2008, 35 Suppl 1:S75-S81.
20. Zhuang Z.P., Kung M.P., Wilson A., Lee C.W., Plössl K., Hou C., et al. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting β-amyloid plaques in the brain. J Med Chem 2003, 46:237-243.
21. 123I]YP256) a potential serotonin transporter radiotracer). Nucl Med Biol 2008, 35:53-59.
22. Watanabe H., Ono M., Kimura H., Kagawa S., Nishii R., Fuchigami T., et al. A dual fluorinated and iodinated radiotracer for PET and SPECT imaging of β-amyloid plaques in the brain. Bioorg Med Chem Lett 2011, 21:6519-6522.
23. Cheng Y., Ono M., Kimura H., Ueda M., Saji H. Technetium-99m labeled pyridyl benzofuran derivatives as single photon emission computed tomography imaging probes for β-amyloid plaques in Alzheimer's brains. J Med Chem 2012, 55:2279-2286.
24. 99mTc-labeled dibenzylideneacetone derivatives as potential SPECT probes for in vivo imaging of β-amyloid plaque. Eur J Med Chem 2013, 64:90-98.
25. Zhang X.L., Ran C.Z. Dual functional small molecule probes as fluorophore and ligand for misfolding proteins. Curr Org Chem 2013, 17:580-593.
26. Golde T.E., Bacskai B.J. Bringing amyloid into focus. Nat Biotechnol 2005, 23:552-554.
27. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003, 46:2740-2754.
28. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
29. 11C-labeled stilbene derivatives as Aβ-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 2003, 30:565-571.
30. 11C]SB-13 PET. Am J Geriatr Psychiatry 2004, 12:584-595.
31. Johnson A.E., Jeppsson F., Sandell J., Wensbo D., Neelissen J.A., Juréus A., et al. AZD2184: a radioligand for sensitive detection of β-amyloid deposits. J Neurochem 2009, 108:1177-1186.
32. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010, 68:319-329.
33. Juréus A., Swahn B.M., Sandell J., Jeppsson F., Johnson A.E., Johnström P., et al. Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand. J Neurochem 2010, 114:784-794.
34. 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med 2012, 53:415-424.
35. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. J Neurosci 2001, 21:RC189.
36. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., et al. Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002, 10:24-35.
37. Zhang W., Oya S., Kung M.P., Hou C., Maier D.L., Kung H.F. F-18 polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain. Nucl Med Biol 2005, 32:799-809.
38. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135.
39. 18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011, 10:424-435.
40. 18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. Nucl Med Biol 2007, 34:89-97.
41. 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 2009, 50:1887-1894.
42. 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010, 51:913-920.
43. Williams S.C.P. Alzheimer's imaging agents struggle to find a market outside trials. Nat Med 2013, 19:1551.
44. Ntziachristos V., Bremer C., Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003, 13:195-208.
45. Ntziachristos V. Fluorescence molecular imaging. Annu Rev Biomed Eng 2006, 8:1-33.
46. Frangioni J.V. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003, 7:626-634.
47. Licha K., Olbrich C. Optical imaging in drug discovery and diagnostic applications. Adv Drug Deliv Rev 2005, 57:1087-1108.
48. Nesterov E.E., Skoch J., Hyman B.T., Klunk W.E., Bacskai B.J., Swager T.M. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew Chem Int Ed Engl 2005, 44:5452-5456.
49. Hintersteiner M., Enz A., Frey P., Jaton A.L., Kinzy W., Kneuer R., et al. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 2005, 23:577-583.
50. Ran C., Xu X., Raymond S.B., Ferrara B.J., Neal K., Bacskai B.J., et al. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits. J Am Chem Soc 2009, 131:15257-15261.
51. Ametamey S.M., Honer M., Schubiger P.A. Molecular imaging with PET. Chem Rev 2008, 108:1501-1516.
52. Clark DE. Computational prediction of blood-brain barrier permeation. Doherty A, editor. Annual reports in medicinal chemistry, San Diego: Elsevier Academic Press; 2005. p. 403-15.
53. Raymond S.B., Skoch J., Hills I.D., Nesterov E.E., Swager T.M., Bacskai B.J. Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging 2008, 35 Suppl 1:S93-S98.
54. Okamura N., Mori M., Furumoto S., Yoshikawa T., Harada R., Ito S., et al. In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-265. J Alzheimers Dis 2011, 23:37-48.
55. Ran C., Moore A. Spectral unmixing imaging of wavelength-responsive fluorescent probes: an application for the real-time report of amyloid β species in Alzheimer's disease. Mol Imaging Biol 2012, 14:293-300.
56. Zhang X.L., Tian Y.L., Li Z., Tian X.Y., Sun H.B., Liu H., et al. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid β species in Alzheimer's disease. J Am Chem Soc 2013, 135:16397-16409.
57. Ono M., Ishikawa M., Kimura H., Hayashi S., Matsumura K., Watanabe H., et al. Development of dual functional SPECT/fluorescent probes for imaging cerebral β-amyloid plaques. Bioorg Med Chem Lett 2010, 20:3885-3888.
58. Ono M., Watanabe H., Kimura H., Saji H. BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques. ACS Chem Neurosci 2012, 3:319-324.
59. Watanabe H., Ono M., Matsumura K., Yoshimura M., Kimura H., Saji H. Molecular imaging of β-amyloid plaques with near-infrared boron dipyrromethane (BODIPY)-based fluorescent probes. Mol Imaging 2013, 12:338-347.
60. Cui M.C., Ono M., Watanabe H., Kimura H., Liu B.L., Saji H. Smart near-infrared fluorescence probes with donor-acceptor structure for in vivo detection of β-amyloid deposits. J Am Chem Soc 2014, 136:3388-3394.
61. Fu H., Cui M., Tu P., Pan Z., Liu B. Evaluation of molecules based on the electron donor-acceptor architecture as near-infrared β-amyloidal-targeting probes. Chem Commun 2014, 50:11875-11878.
62. Cui M.C. Past and recent progress of molecular imaging probes for β-amyloid plaques in the brain. Curr Med Chem 2014, 21:82-112.
63. Meyers F., Marder S.R., Pierce B.M., Bredas J.L. Electric-field modulated nonlinear-optical properties of donor-acceptor polyenes: sum-over-states investigation of the relationship between molecular polarizabilities (α, β and γ) and bond-length alternation. J Am Chem Soc 1994, 116:10703-10714.
64. Brandenburg E., von Berlepsch H., Koksch B. Specific in situ discrimination of amyloid fibrils versus α-helical fibres by the fluorophore NIAD-4. Mol BioSyst 2012, 8:557-564.
65. Meek S.T., Nesterov E.E., Swager T.M. Near-infrared fluorophores containing benzo[c]heterocycle subunits. Org Lett 2008, 10:2991-2993.
66. Ran C.Z., Zhao W., Moir R.D., Moore A. Non-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid β species. PLoS One 2011, 6:e19362.
67. Schmidt A., Pahnke J. Efficient near-infrared in vivo imaging of amyoid-β deposits in Alzheimer's disease mouse models. J Alzheimers Dis 2012, 30:651-664.